Sector News

Allergan CEO tamps down Biogen buyout rumors

August 8, 2016
Life sciences

Allergan may have a reputation as a serial buyer, but it’s not looking for any big deals, CEO Brent Saunders insisted on Monday. And that assurance could quiet the rumors that the company is eyeing a Biogen buy.

As Saunders pointed out on Allergan’s Q2 conference call, the company has been focused on so-called “stepping stone” deals, and that’s what it’s looking at now.

Allergan’s recently canceled Pfizer megamerger notwithstanding, “It’s not like it’s a new strategy, despite our image … in the market,” he said.

That was a “once in a corporate lifetime situation,” Saunders insisted. These days, “we’re not looking for big M&A,” he said, though “while the odds of something compelling become clear are exceptionally low,” they’re “not zero,” he pointed out.

Meanwhile, in the wake of Allergan’s just-closed deal to send its generics unit off to Teva–and another recent pact that’ll transfer its generics distribution business to the Israeli drugmaker, too–Teva’s base business “looks good,” Evercore ISI analyst Umer Raffat wrote in a note to clients. Key products Botox and Restasis netted $719.7 million and $390.6 million in quarterly sales, respectively, with their year-over-year growth offsetting a $38.2 million decline for now-off-patent Alzheimer’s med Namenda.

Overall, the heavy hitters led revenue to $3.68 billion–and while that figure fell short of the $4.08 billion consensus mark, that consensus hadn’t been updated for the generics distribution sale, Raffat pointed out. Allergan put up a net loss of $1.44 per share, which has widened since the company posted a loss of 80 cents in the year-ago period.

Allergan’s full-year guidance suffered on the distribution deal, too; while the business primarily supported the company’s former generics unit, branded revenues took a $100 million hit, leading the Dublin drugmaker to revise its sales guidance downward. It now expects between $14.75 billion and $15 billion for the year, as opposed to the $15 billion it previously forecast.

By Carly Helfan

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).